nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—Hexylcaine—SCN10A—melanoma	0.00655	1	CrCbGaD
Methylphenidate—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A11—melanoma	0.00327	0.0589	CbGpPWpGaD
Methylphenidate—SLC6A3—Na+/Cl- dependent neurotransmitter transporters—SLC6A11—melanoma	0.00289	0.0522	CbGpPWpGaD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—CDKN1C—melanoma	0.00251	0.0453	CbGpPWpGaD
Methylphenidate—SLC6A2—Amine compound SLC transporters—SLC6A11—melanoma	0.00227	0.0409	CbGpPWpGaD
Methylphenidate—SLC6A3—Amine compound SLC transporters—SLC6A11—melanoma	0.00201	0.0362	CbGpPWpGaD
Methylphenidate—SLC6A4—Serotonin Transporter Activity—ITGB3—melanoma	0.00189	0.034	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—SLC39A12—melanoma	0.00162	0.0292	CbGpPWpGaD
Methylphenidate—Angiopathy—Temozolomide—melanoma	0.00142	0.00152	CcSEcCtD
Methylphenidate—Mental disorder—Carmustine—melanoma	0.00142	0.00152	CcSEcCtD
Methylphenidate—Immune system disorder—Temozolomide—melanoma	0.00142	0.00151	CcSEcCtD
Methylphenidate—Mediastinal disorder—Temozolomide—melanoma	0.00141	0.00151	CcSEcCtD
Methylphenidate—Malnutrition—Carmustine—melanoma	0.00141	0.00151	CcSEcCtD
Methylphenidate—Erythema—Carmustine—melanoma	0.00141	0.00151	CcSEcCtD
Methylphenidate—Cough—Bleomycin—melanoma	0.00141	0.00151	CcSEcCtD
Methylphenidate—Chills—Temozolomide—melanoma	0.00141	0.0015	CcSEcCtD
Methylphenidate—Dehydration—Docetaxel—melanoma	0.0014	0.0015	CcSEcCtD
Methylphenidate—Ill-defined disorder—Dactinomycin—melanoma	0.0014	0.00149	CcSEcCtD
Methylphenidate—Anaemia—Dactinomycin—melanoma	0.0014	0.00149	CcSEcCtD
Methylphenidate—Liver function test abnormal—Docetaxel—melanoma	0.00139	0.00148	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—SLC39A12—melanoma	0.00139	0.0251	CbGpPWpGaD
Methylphenidate—Vomiting—Vemurafenib—melanoma	0.00139	0.00148	CcSEcCtD
Methylphenidate—Alopecia—Temozolomide—melanoma	0.00139	0.00148	CcSEcCtD
Methylphenidate—Chest pain—Bleomycin—melanoma	0.00138	0.00147	CcSEcCtD
Methylphenidate—Myalgia—Bleomycin—melanoma	0.00138	0.00147	CcSEcCtD
Methylphenidate—Abdominal pain upper—Docetaxel—melanoma	0.00138	0.00147	CcSEcCtD
Methylphenidate—Rash—Vemurafenib—melanoma	0.00138	0.00147	CcSEcCtD
Methylphenidate—Mental disorder—Temozolomide—melanoma	0.00137	0.00147	CcSEcCtD
Methylphenidate—Dermatitis—Vemurafenib—melanoma	0.00137	0.00147	CcSEcCtD
Methylphenidate—Back pain—Carmustine—melanoma	0.00137	0.00146	CcSEcCtD
Methylphenidate—Headache—Vemurafenib—melanoma	0.00137	0.00146	CcSEcCtD
Methylphenidate—Malnutrition—Temozolomide—melanoma	0.00137	0.00146	CcSEcCtD
Methylphenidate—Erythema—Temozolomide—melanoma	0.00137	0.00146	CcSEcCtD
Methylphenidate—Breast disorder—Docetaxel—melanoma	0.00136	0.00145	CcSEcCtD
Methylphenidate—Discomfort—Bleomycin—melanoma	0.00136	0.00145	CcSEcCtD
Methylphenidate—Malaise—Dactinomycin—melanoma	0.00136	0.00145	CcSEcCtD
Methylphenidate—Cramp muscle—Docetaxel—melanoma	0.00136	0.00145	CcSEcCtD
Methylphenidate—Leukopenia—Dactinomycin—melanoma	0.00135	0.00144	CcSEcCtD
Methylphenidate—Nasopharyngitis—Docetaxel—melanoma	0.00135	0.00144	CcSEcCtD
Methylphenidate—Confusional state—Bleomycin—melanoma	0.00133	0.00142	CcSEcCtD
Methylphenidate—Vision blurred—Carmustine—melanoma	0.00133	0.00142	CcSEcCtD
Methylphenidate—Alanine aminotransferase increased—Docetaxel—melanoma	0.00133	0.00142	CcSEcCtD
Methylphenidate—Tremor—Carmustine—melanoma	0.00132	0.00141	CcSEcCtD
Methylphenidate—Oedema—Bleomycin—melanoma	0.00132	0.00141	CcSEcCtD
Methylphenidate—Anaphylactic shock—Bleomycin—melanoma	0.00132	0.00141	CcSEcCtD
Methylphenidate—Back pain—Temozolomide—melanoma	0.00132	0.00141	CcSEcCtD
Methylphenidate—Infection—Bleomycin—melanoma	0.00131	0.0014	CcSEcCtD
Methylphenidate—Anaemia—Carmustine—melanoma	0.00131	0.00139	CcSEcCtD
Methylphenidate—Agitation—Carmustine—melanoma	0.0013	0.00138	CcSEcCtD
Methylphenidate—Nausea—Vemurafenib—melanoma	0.0013	0.00138	CcSEcCtD
Methylphenidate—Thrombocytopenia—Bleomycin—melanoma	0.00129	0.00138	CcSEcCtD
Methylphenidate—Vision blurred—Temozolomide—melanoma	0.00129	0.00137	CcSEcCtD
Methylphenidate—Myalgia—Dactinomycin—melanoma	0.00129	0.00137	CcSEcCtD
Methylphenidate—Tremor—Temozolomide—melanoma	0.00128	0.00136	CcSEcCtD
Methylphenidate—Discomfort—Dactinomycin—melanoma	0.00127	0.00135	CcSEcCtD
Methylphenidate—Angina pectoris—Docetaxel—melanoma	0.00127	0.00135	CcSEcCtD
Methylphenidate—Ill-defined disorder—Temozolomide—melanoma	0.00127	0.00135	CcSEcCtD
Methylphenidate—Leukopenia—Carmustine—melanoma	0.00127	0.00135	CcSEcCtD
Methylphenidate—Anaemia—Temozolomide—melanoma	0.00126	0.00135	CcSEcCtD
Methylphenidate—Anorexia—Bleomycin—melanoma	0.00126	0.00134	CcSEcCtD
Methylphenidate—Agitation—Temozolomide—melanoma	0.00126	0.00134	CcSEcCtD
Methylphenidate—Angioedema—Temozolomide—melanoma	0.00125	0.00133	CcSEcCtD
Methylphenidate—Pancytopenia—Docetaxel—melanoma	0.00124	0.00132	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—SLC39A12—melanoma	0.00123	0.0222	CbGpPWpGaD
Methylphenidate—Oedema—Dactinomycin—melanoma	0.00123	0.00131	CcSEcCtD
Methylphenidate—Malaise—Temozolomide—melanoma	0.00123	0.00131	CcSEcCtD
Methylphenidate—Vertigo—Temozolomide—melanoma	0.00123	0.00131	CcSEcCtD
Methylphenidate—Convulsion—Carmustine—melanoma	0.00122	0.00131	CcSEcCtD
Methylphenidate—Infection—Dactinomycin—melanoma	0.00122	0.00131	CcSEcCtD
Methylphenidate—Leukopenia—Temozolomide—melanoma	0.00122	0.0013	CcSEcCtD
Methylphenidate—Hypertension—Carmustine—melanoma	0.00122	0.0013	CcSEcCtD
Methylphenidate—Palpitations—Temozolomide—melanoma	0.00121	0.00129	CcSEcCtD
Methylphenidate—Thrombocytopenia—Dactinomycin—melanoma	0.00121	0.00129	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Bleomycin—melanoma	0.0012	0.00128	CcSEcCtD
Methylphenidate—Myalgia—Carmustine—melanoma	0.0012	0.00128	CcSEcCtD
Methylphenidate—Chest pain—Carmustine—melanoma	0.0012	0.00128	CcSEcCtD
Methylphenidate—Anxiety—Carmustine—melanoma	0.0012	0.00128	CcSEcCtD
Methylphenidate—Cough—Temozolomide—melanoma	0.00119	0.00127	CcSEcCtD
Methylphenidate—Paraesthesia—Bleomycin—melanoma	0.00119	0.00127	CcSEcCtD
Methylphenidate—Weight increased—Docetaxel—melanoma	0.00119	0.00126	CcSEcCtD
Methylphenidate—Convulsion—Temozolomide—melanoma	0.00118	0.00126	CcSEcCtD
Methylphenidate—Weight decreased—Docetaxel—melanoma	0.00118	0.00126	CcSEcCtD
Methylphenidate—Hypertension—Temozolomide—melanoma	0.00118	0.00126	CcSEcCtD
Methylphenidate—Dyspnoea—Bleomycin—melanoma	0.00118	0.00126	CcSEcCtD
Methylphenidate—Anorexia—Dactinomycin—melanoma	0.00117	0.00125	CcSEcCtD
Methylphenidate—Pneumonia—Docetaxel—melanoma	0.00117	0.00125	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—POU3F2—melanoma	0.00116	0.021	CbGpPWpGaD
Methylphenidate—Confusional state—Carmustine—melanoma	0.00116	0.00124	CcSEcCtD
Methylphenidate—Arthralgia—Temozolomide—melanoma	0.00116	0.00124	CcSEcCtD
Methylphenidate—Myalgia—Temozolomide—melanoma	0.00116	0.00124	CcSEcCtD
Methylphenidate—Infestation—Docetaxel—melanoma	0.00116	0.00124	CcSEcCtD
Methylphenidate—Infestation NOS—Docetaxel—melanoma	0.00116	0.00124	CcSEcCtD
Methylphenidate—Anxiety—Temozolomide—melanoma	0.00116	0.00124	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00115	0.00123	CcSEcCtD
Methylphenidate—Oedema—Carmustine—melanoma	0.00115	0.00123	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Docetaxel—melanoma	0.00115	0.00123	CcSEcCtD
Methylphenidate—Discomfort—Temozolomide—melanoma	0.00115	0.00123	CcSEcCtD
Methylphenidate—Decreased appetite—Bleomycin—melanoma	0.00115	0.00122	CcSEcCtD
Methylphenidate—Infection—Carmustine—melanoma	0.00115	0.00122	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Docetaxel—melanoma	0.00115	0.00122	CcSEcCtD
Methylphenidate—Myocardial infarction—Docetaxel—melanoma	0.00114	0.00121	CcSEcCtD
Methylphenidate—Dry mouth—Temozolomide—melanoma	0.00114	0.00121	CcSEcCtD
Methylphenidate—Pain—Bleomycin—melanoma	0.00113	0.0012	CcSEcCtD
Methylphenidate—Conjunctivitis—Docetaxel—melanoma	0.00113	0.0012	CcSEcCtD
Methylphenidate—Thrombocytopenia—Carmustine—melanoma	0.00113	0.0012	CcSEcCtD
Methylphenidate—Tachycardia—Carmustine—melanoma	0.00113	0.0012	CcSEcCtD
Methylphenidate—Confusional state—Temozolomide—melanoma	0.00112	0.0012	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00112	0.0012	CcSEcCtD
Methylphenidate—Oedema—Temozolomide—melanoma	0.00111	0.00119	CcSEcCtD
Methylphenidate—Anaphylactic shock—Temozolomide—melanoma	0.00111	0.00119	CcSEcCtD
Methylphenidate—Infection—Temozolomide—melanoma	0.00111	0.00118	CcSEcCtD
Methylphenidate—Anorexia—Carmustine—melanoma	0.0011	0.00117	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Docetaxel—melanoma	0.0011	0.00117	CcSEcCtD
Methylphenidate—Epistaxis—Docetaxel—melanoma	0.0011	0.00117	CcSEcCtD
Methylphenidate—Nervous system disorder—Temozolomide—melanoma	0.00109	0.00117	CcSEcCtD
Methylphenidate—Thrombocytopenia—Temozolomide—melanoma	0.00109	0.00116	CcSEcCtD
Methylphenidate—Feeling abnormal—Bleomycin—melanoma	0.00109	0.00116	CcSEcCtD
Methylphenidate—Skin disorder—Temozolomide—melanoma	0.00108	0.00115	CcSEcCtD
Methylphenidate—Hyperhidrosis—Temozolomide—melanoma	0.00108	0.00115	CcSEcCtD
Methylphenidate—Decreased appetite—Dactinomycin—melanoma	0.00107	0.00114	CcSEcCtD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—APAF1—melanoma	0.00107	0.0193	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—RAI1—melanoma	0.00107	0.0192	CbGpPWpGaD
Methylphenidate—Fatigue—Dactinomycin—melanoma	0.00106	0.00113	CcSEcCtD
Methylphenidate—Anorexia—Temozolomide—melanoma	0.00106	0.00113	CcSEcCtD
Methylphenidate—Pain—Dactinomycin—melanoma	0.00105	0.00112	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Carmustine—melanoma	0.00105	0.00112	CcSEcCtD
Methylphenidate—Urticaria—Bleomycin—melanoma	0.00105	0.00112	CcSEcCtD
Methylphenidate—Haemoglobin—Docetaxel—melanoma	0.00105	0.00112	CcSEcCtD
Methylphenidate—Rhinitis—Docetaxel—melanoma	0.00105	0.00112	CcSEcCtD
Methylphenidate—Body temperature increased—Bleomycin—melanoma	0.00104	0.00111	CcSEcCtD
Methylphenidate—Haemorrhage—Docetaxel—melanoma	0.00104	0.00111	CcSEcCtD
Methylphenidate—Insomnia—Carmustine—melanoma	0.00104	0.00111	CcSEcCtD
Methylphenidate—Paraesthesia—Carmustine—melanoma	0.00104	0.0011	CcSEcCtD
Methylphenidate—Pharyngitis—Docetaxel—melanoma	0.00104	0.0011	CcSEcCtD
Methylphenidate—Urinary tract disorder—Docetaxel—melanoma	0.00103	0.0011	CcSEcCtD
Methylphenidate—Dyspnoea—Carmustine—melanoma	0.00103	0.0011	CcSEcCtD
Methylphenidate—Somnolence—Carmustine—melanoma	0.00103	0.00109	CcSEcCtD
Methylphenidate—Connective tissue disorder—Docetaxel—melanoma	0.00103	0.00109	CcSEcCtD
Methylphenidate—Urethral disorder—Docetaxel—melanoma	0.00102	0.00109	CcSEcCtD
Methylphenidate—Feeling abnormal—Dactinomycin—melanoma	0.00102	0.00108	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Temozolomide—melanoma	0.00102	0.00108	CcSEcCtD
Methylphenidate—Insomnia—Temozolomide—melanoma	0.00101	0.00108	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Dactinomycin—melanoma	0.00101	0.00107	CcSEcCtD
Methylphenidate—Visual impairment—Docetaxel—melanoma	0.00101	0.00107	CcSEcCtD
Methylphenidate—Decreased appetite—Carmustine—melanoma	0.001	0.00107	CcSEcCtD
Methylphenidate—Paraesthesia—Temozolomide—melanoma	0.001	0.00107	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Carmustine—melanoma	0.000996	0.00106	CcSEcCtD
Methylphenidate—Dyspnoea—Temozolomide—melanoma	0.000994	0.00106	CcSEcCtD
Methylphenidate—Somnolence—Temozolomide—melanoma	0.000991	0.00106	CcSEcCtD
Methylphenidate—Erythema multiforme—Docetaxel—melanoma	0.000987	0.00105	CcSEcCtD
Methylphenidate—Pain—Carmustine—melanoma	0.000987	0.00105	CcSEcCtD
Methylphenidate—Constipation—Carmustine—melanoma	0.000987	0.00105	CcSEcCtD
Methylphenidate—Dyspepsia—Temozolomide—melanoma	0.000981	0.00105	CcSEcCtD
Methylphenidate—Eye disorder—Docetaxel—melanoma	0.000975	0.00104	CcSEcCtD
Methylphenidate—Abdominal pain—Dactinomycin—melanoma	0.000974	0.00104	CcSEcCtD
Methylphenidate—Body temperature increased—Dactinomycin—melanoma	0.000974	0.00104	CcSEcCtD
Methylphenidate—Hypersensitivity—Bleomycin—melanoma	0.000974	0.00104	CcSEcCtD
Methylphenidate—Decreased appetite—Temozolomide—melanoma	0.000969	0.00103	CcSEcCtD
Methylphenidate—Cardiac disorder—Docetaxel—melanoma	0.000969	0.00103	CcSEcCtD
Methylphenidate—Flushing—Docetaxel—melanoma	0.000969	0.00103	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Temozolomide—melanoma	0.000963	0.00103	CcSEcCtD
Methylphenidate—Fatigue—Temozolomide—melanoma	0.000961	0.00102	CcSEcCtD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—PTK2B—melanoma	0.000956	0.0172	CbGpPWpGaD
Methylphenidate—Pain—Temozolomide—melanoma	0.000953	0.00102	CcSEcCtD
Methylphenidate—Constipation—Temozolomide—melanoma	0.000953	0.00102	CcSEcCtD
Methylphenidate—Feeling abnormal—Carmustine—melanoma	0.000951	0.00101	CcSEcCtD
Methylphenidate—Asthenia—Bleomycin—melanoma	0.000948	0.00101	CcSEcCtD
Methylphenidate—Angiopathy—Docetaxel—melanoma	0.000947	0.00101	CcSEcCtD
Methylphenidate—CYP2D6—Codeine and Morphine Metabolism—ABCB1—melanoma	0.000945	0.017	CbGpPWpGaD
Methylphenidate—Gastrointestinal pain—Carmustine—melanoma	0.000943	0.00101	CcSEcCtD
Methylphenidate—Immune system disorder—Docetaxel—melanoma	0.000943	0.001	CcSEcCtD
Methylphenidate—Mediastinal disorder—Docetaxel—melanoma	0.000941	0.001	CcSEcCtD
Methylphenidate—Chills—Docetaxel—melanoma	0.000936	0.000998	CcSEcCtD
Methylphenidate—Pruritus—Bleomycin—melanoma	0.000935	0.000997	CcSEcCtD
Methylphenidate—Arrhythmia—Docetaxel—melanoma	0.000932	0.000994	CcSEcCtD
Methylphenidate—Alopecia—Docetaxel—melanoma	0.000922	0.000983	CcSEcCtD
Methylphenidate—Feeling abnormal—Temozolomide—melanoma	0.000919	0.000979	CcSEcCtD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—MAP2—melanoma	0.000917	0.0165	CbGpPWpGaD
Methylphenidate—Mental disorder—Docetaxel—melanoma	0.000914	0.000975	CcSEcCtD
Methylphenidate—Abdominal pain—Carmustine—melanoma	0.000912	0.000972	CcSEcCtD
Methylphenidate—Body temperature increased—Carmustine—melanoma	0.000912	0.000972	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Temozolomide—melanoma	0.000912	0.000972	CcSEcCtD
Methylphenidate—Malnutrition—Docetaxel—melanoma	0.000908	0.000969	CcSEcCtD
Methylphenidate—Erythema—Docetaxel—melanoma	0.000908	0.000969	CcSEcCtD
Methylphenidate—Hypersensitivity—Dactinomycin—melanoma	0.000908	0.000968	CcSEcCtD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A11—melanoma	0.000887	0.016	CbGpPWpGaD
Methylphenidate—Urticaria—Temozolomide—melanoma	0.000886	0.000944	CcSEcCtD
Methylphenidate—Asthenia—Dactinomycin—melanoma	0.000884	0.000943	CcSEcCtD
Methylphenidate—Abdominal pain—Temozolomide—melanoma	0.000881	0.00094	CcSEcCtD
Methylphenidate—Body temperature increased—Temozolomide—melanoma	0.000881	0.00094	CcSEcCtD
Methylphenidate—Back pain—Docetaxel—melanoma	0.000879	0.000937	CcSEcCtD
Methylphenidate—Muscle spasms—Docetaxel—melanoma	0.000873	0.000931	CcSEcCtD
Methylphenidate—Hypersensitivity—Carmustine—melanoma	0.00085	0.000906	CcSEcCtD
Methylphenidate—Diarrhoea—Dactinomycin—melanoma	0.000843	0.000899	CcSEcCtD
Methylphenidate—Vomiting—Bleomycin—melanoma	0.00084	0.000896	CcSEcCtD
Methylphenidate—Anaemia—Docetaxel—melanoma	0.00084	0.000895	CcSEcCtD
Methylphenidate—Rash—Bleomycin—melanoma	0.000833	0.000888	CcSEcCtD
Methylphenidate—Dermatitis—Bleomycin—melanoma	0.000833	0.000888	CcSEcCtD
Methylphenidate—Asthenia—Carmustine—melanoma	0.000828	0.000882	CcSEcCtD
Methylphenidate—Hypersensitivity—Temozolomide—melanoma	0.000821	0.000876	CcSEcCtD
Methylphenidate—Syncope—Docetaxel—melanoma	0.000815	0.000869	CcSEcCtD
Methylphenidate—Leukopenia—Docetaxel—melanoma	0.000813	0.000867	CcSEcCtD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—SYK—melanoma	0.000813	0.0146	CbGpPWpGaD
Methylphenidate—SLC6A4—Monoamine Transport—ITGB3—melanoma	0.000804	0.0145	CbGpPWpGaD
Methylphenidate—Palpitations—Docetaxel—melanoma	0.000803	0.000856	CcSEcCtD
Methylphenidate—Asthenia—Temozolomide—melanoma	0.0008	0.000853	CcSEcCtD
Methylphenidate—Loss of consciousness—Docetaxel—melanoma	0.000798	0.000851	CcSEcCtD
Methylphenidate—Cough—Docetaxel—melanoma	0.000793	0.000845	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—EPHA2—melanoma	0.000791	0.0143	CbGpPWpGaD
Methylphenidate—Diarrhoea—Carmustine—melanoma	0.000789	0.000842	CcSEcCtD
Methylphenidate—Pruritus—Temozolomide—melanoma	0.000789	0.000841	CcSEcCtD
Methylphenidate—Convulsion—Docetaxel—melanoma	0.000787	0.000839	CcSEcCtD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A11—melanoma	0.000786	0.0142	CbGpPWpGaD
Methylphenidate—Nausea—Bleomycin—melanoma	0.000785	0.000837	CcSEcCtD
Methylphenidate—Hypertension—Docetaxel—melanoma	0.000784	0.000836	CcSEcCtD
Methylphenidate—Vomiting—Dactinomycin—melanoma	0.000784	0.000836	CcSEcCtD
Methylphenidate—Rash—Dactinomycin—melanoma	0.000777	0.000829	CcSEcCtD
Methylphenidate—Chest pain—Docetaxel—melanoma	0.000773	0.000825	CcSEcCtD
Methylphenidate—Arthralgia—Docetaxel—melanoma	0.000773	0.000825	CcSEcCtD
Methylphenidate—Myalgia—Docetaxel—melanoma	0.000773	0.000825	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000768	0.000819	CcSEcCtD
Methylphenidate—Dizziness—Carmustine—melanoma	0.000763	0.000813	CcSEcCtD
Methylphenidate—Diarrhoea—Temozolomide—melanoma	0.000763	0.000813	CcSEcCtD
Methylphenidate—Dry mouth—Docetaxel—melanoma	0.000756	0.000806	CcSEcCtD
Methylphenidate—Confusional state—Docetaxel—melanoma	0.000748	0.000797	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—SLC6A11—melanoma	0.000744	0.0134	CbGpPWpGaD
Methylphenidate—Anaphylactic shock—Docetaxel—melanoma	0.000741	0.00079	CcSEcCtD
Methylphenidate—Oedema—Docetaxel—melanoma	0.000741	0.00079	CcSEcCtD
Methylphenidate—Dizziness—Temozolomide—melanoma	0.000737	0.000786	CcSEcCtD
Methylphenidate—Infection—Docetaxel—melanoma	0.000737	0.000785	CcSEcCtD
Methylphenidate—Vomiting—Carmustine—melanoma	0.000734	0.000782	CcSEcCtD
Methylphenidate—Nausea—Dactinomycin—melanoma	0.000732	0.000781	CcSEcCtD
Methylphenidate—Shock—Docetaxel—melanoma	0.000729	0.000778	CcSEcCtD
Methylphenidate—Rash—Carmustine—melanoma	0.000727	0.000776	CcSEcCtD
Methylphenidate—Nervous system disorder—Docetaxel—melanoma	0.000727	0.000775	CcSEcCtD
Methylphenidate—Dermatitis—Carmustine—melanoma	0.000727	0.000775	CcSEcCtD
Methylphenidate—Thrombocytopenia—Docetaxel—melanoma	0.000726	0.000774	CcSEcCtD
Methylphenidate—Tachycardia—Docetaxel—melanoma	0.000724	0.000771	CcSEcCtD
Methylphenidate—Headache—Carmustine—melanoma	0.000723	0.000771	CcSEcCtD
Methylphenidate—Skin disorder—Docetaxel—melanoma	0.00072	0.000768	CcSEcCtD
Methylphenidate—Vomiting—Temozolomide—melanoma	0.000709	0.000756	CcSEcCtD
Methylphenidate—Anorexia—Docetaxel—melanoma	0.000707	0.000753	CcSEcCtD
Methylphenidate—Rash—Temozolomide—melanoma	0.000703	0.000749	CcSEcCtD
Methylphenidate—Dermatitis—Temozolomide—melanoma	0.000702	0.000749	CcSEcCtD
Methylphenidate—Headache—Temozolomide—melanoma	0.000698	0.000745	CcSEcCtD
Methylphenidate—SLC6A2—Monoamine Transport—ITGB3—melanoma	0.000691	0.0125	CbGpPWpGaD
Methylphenidate—Nausea—Carmustine—melanoma	0.000685	0.000731	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—EPHA2—melanoma	0.00068	0.0123	CbGpPWpGaD
Methylphenidate—Musculoskeletal discomfort—Docetaxel—melanoma	0.000675	0.00072	CcSEcCtD
Methylphenidate—Insomnia—Docetaxel—melanoma	0.000671	0.000715	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—MAP2—melanoma	0.000668	0.0121	CbGpPWpGaD
Methylphenidate—Paraesthesia—Docetaxel—melanoma	0.000666	0.00071	CcSEcCtD
Methylphenidate—Nausea—Temozolomide—melanoma	0.000662	0.000706	CcSEcCtD
Methylphenidate—Dyspnoea—Docetaxel—melanoma	0.000661	0.000705	CcSEcCtD
Methylphenidate—Somnolence—Docetaxel—melanoma	0.000659	0.000703	CcSEcCtD
Methylphenidate—Dyspepsia—Docetaxel—melanoma	0.000653	0.000696	CcSEcCtD
Methylphenidate—Decreased appetite—Docetaxel—melanoma	0.000645	0.000687	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Docetaxel—melanoma	0.00064	0.000682	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—SLC6A11—melanoma	0.000639	0.0115	CbGpPWpGaD
Methylphenidate—Fatigue—Docetaxel—melanoma	0.000639	0.000681	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—ARNT—melanoma	0.000634	0.0114	CbGpPWpGaD
Methylphenidate—Pain—Docetaxel—melanoma	0.000634	0.000676	CcSEcCtD
Methylphenidate—Constipation—Docetaxel—melanoma	0.000634	0.000676	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—PAX4—melanoma	0.000612	0.011	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—ITGB3—melanoma	0.000612	0.011	CbGpPWpGaD
Methylphenidate—Feeling abnormal—Docetaxel—melanoma	0.000611	0.000651	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Docetaxel—melanoma	0.000606	0.000646	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—EPHA2—melanoma	0.000602	0.0109	CbGpPWpGaD
Methylphenidate—Abdominal pain—Docetaxel—melanoma	0.000586	0.000625	CcSEcCtD
Methylphenidate—Body temperature increased—Docetaxel—melanoma	0.000586	0.000625	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TP73—melanoma	0.000568	0.0102	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SLC6A11—melanoma	0.000566	0.0102	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Docetaxel—melanoma	0.000546	0.000582	CcSEcCtD
Methylphenidate—Asthenia—Docetaxel—melanoma	0.000532	0.000567	CcSEcCtD
Methylphenidate—CYP2D6—Tamoxifen metabolism—CYP1B1—melanoma	0.00053	0.00955	CbGpPWpGaD
Methylphenidate—Pruritus—Docetaxel—melanoma	0.000525	0.000559	CcSEcCtD
Methylphenidate—Diarrhoea—Docetaxel—melanoma	0.000507	0.000541	CcSEcCtD
Methylphenidate—Dizziness—Docetaxel—melanoma	0.00049	0.000523	CcSEcCtD
Methylphenidate—Vomiting—Docetaxel—melanoma	0.000471	0.000503	CcSEcCtD
Methylphenidate—Rash—Docetaxel—melanoma	0.000467	0.000498	CcSEcCtD
Methylphenidate—Dermatitis—Docetaxel—melanoma	0.000467	0.000498	CcSEcCtD
Methylphenidate—Headache—Docetaxel—melanoma	0.000464	0.000495	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC15A2—melanoma	0.000461	0.00831	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCB5—melanoma	0.000446	0.00804	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC17A5—melanoma	0.000444	0.008	CbGpPWpGaD
Methylphenidate—Nausea—Docetaxel—melanoma	0.00044	0.00047	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—SLC6A11—melanoma	0.00044	0.00794	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—CYP1B1—melanoma	0.000409	0.00738	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC15A2—melanoma	0.000408	0.00736	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC6A11—melanoma	0.000403	0.00726	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCB5—melanoma	0.000395	0.00712	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC17A5—melanoma	0.000393	0.00709	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC6A11—melanoma	0.000357	0.00644	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—UGT2B10—melanoma	0.000351	0.00633	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—SLC5A5—melanoma	0.00034	0.00613	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SLC6A11—melanoma	0.000337	0.00608	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—EDN1—melanoma	0.000331	0.00597	CbGpPWpGaD
Methylphenidate—SLC6A4—Monoamine Transport—TNF—melanoma	0.000323	0.00582	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—PRKCA—melanoma	0.00031	0.00559	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ARL2—melanoma	0.000309	0.00557	CbGpPWpGaD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—STAT3—melanoma	0.000299	0.00539	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CASP3—melanoma	0.000295	0.00531	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—SLC5A5—melanoma	0.000292	0.00527	CbGpPWpGaD
Methylphenidate—SLC6A2—Monoamine Transport—TNF—melanoma	0.000277	0.005	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ARL2—melanoma	0.000274	0.00494	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—GNA11—melanoma	0.000274	0.00493	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP17A1—melanoma	0.000272	0.0049	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GRIN2A—melanoma	0.000269	0.00485	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP17A1—melanoma	0.000268	0.00484	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SLC5A5—melanoma	0.000259	0.00467	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—HDAC2—melanoma	0.000257	0.00464	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—GNAQ—melanoma	0.000254	0.00458	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—HGF—melanoma	0.000252	0.00454	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—TNF—melanoma	0.000246	0.00443	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL10—melanoma	0.000239	0.0043	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—NGFR—melanoma	0.000235	0.00423	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC15A2—melanoma	0.000234	0.00422	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—melanoma	0.000229	0.00413	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—melanoma	0.000226	0.00407	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC17A5—melanoma	0.000226	0.00407	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—AKR1B10—melanoma	0.000223	0.00403	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	0.00022	0.00397	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—HGF—melanoma	0.000216	0.0039	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC15A2—melanoma	0.000208	0.00374	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GRIN2A—melanoma	0.000206	0.00372	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC6A11—melanoma	0.000205	0.00369	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HIF1A—melanoma	0.000201	0.00363	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC17A5—melanoma	0.0002	0.0036	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—HGF—melanoma	0.000192	0.00346	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	0.000186	0.00334	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—melanoma	0.000184	0.00332	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC6A11—melanoma	0.000181	0.00327	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—FAS—melanoma	0.000175	0.00315	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—melanoma	0.000163	0.00294	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—NFKB1—melanoma	0.00016	0.00289	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CDK4—melanoma	0.000154	0.00277	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—NOS2—melanoma	0.000149	0.00269	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—PRKCA—melanoma	0.000141	0.00255	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PPARG—melanoma	0.00014	0.00252	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CXCL8—melanoma	0.000131	0.00235	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CASP3—melanoma	0.000125	0.00225	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—melanoma	0.00012	0.00217	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP17A1—melanoma	0.000117	0.00211	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—NFKB1—melanoma	0.000117	0.00211	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP17A1—melanoma	0.000115	0.00208	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—PRKCA—melanoma	0.000108	0.00195	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—VEGFA—melanoma	0.000106	0.00191	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—BRAF—melanoma	0.000104	0.00188	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP1B1—melanoma	9.85e-05	0.00178	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP1B1—melanoma	9.72e-05	0.00175	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PTEN—melanoma	9.58e-05	0.00173	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC5A5—melanoma	9.36e-05	0.00169	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TNF—melanoma	9.08e-05	0.00164	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—ALB—melanoma	8.79e-05	0.00158	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—MDM2—melanoma	8.72e-05	0.00157	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC5A5—melanoma	8.3e-05	0.0015	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—BRAF—melanoma	7.97e-05	0.00144	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—ALB—melanoma	7.79e-05	0.0014	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL6—melanoma	7.33e-05	0.00132	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCB1—melanoma	7.14e-05	0.00129	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—MDM2—melanoma	6.68e-05	0.0012	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ACER3—melanoma	6.57e-05	0.00118	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TP53—melanoma	6.54e-05	0.00118	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCB1—melanoma	6.33e-05	0.00114	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—UGT2B10—melanoma	6.01e-05	0.00108	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—IL6—melanoma	5.99e-05	0.00108	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—MAPK1—melanoma	5.96e-05	0.00107	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HS3ST5—melanoma	5.59e-05	0.00101	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—HRAS—melanoma	4.78e-05	0.000862	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—MAPK1—melanoma	4.56e-05	0.000823	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ALB—melanoma	4.47e-05	0.000805	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PLCB4—melanoma	4.23e-05	0.000763	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC6A11—melanoma	3.98e-05	0.000717	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIP4K2A—melanoma	3.98e-05	0.000717	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ALB—melanoma	3.96e-05	0.000713	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MTAP—melanoma	3.87e-05	0.000698	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—HRAS—melanoma	3.66e-05	0.000661	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PHGDH—melanoma	3.45e-05	0.000622	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—LUM—melanoma	3.45e-05	0.000622	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HPSE—melanoma	3.38e-05	0.00061	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CUBN—melanoma	3.32e-05	0.000599	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CSPG4—melanoma	3.21e-05	0.000578	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SDHD—melanoma	3.21e-05	0.000578	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—BSG—melanoma	3.21e-05	0.000578	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GPAM—melanoma	3.11e-05	0.00056	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PLA2G6—melanoma	2.64e-05	0.000476	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—VCAN—melanoma	2.37e-05	0.000428	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP17A1—melanoma	2e-05	0.000361	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GNA11—melanoma	1.89e-05	0.000341	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—FASN—melanoma	1.85e-05	0.000334	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC5A5—melanoma	1.82e-05	0.000328	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GNAQ—melanoma	1.76e-05	0.000317	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CD44—melanoma	1.76e-05	0.000317	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP1B1—melanoma	1.69e-05	0.000304	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCB1—melanoma	1.39e-05	0.00025	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PRKCA—melanoma	1.28e-05	0.00023	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ERCC2—melanoma	1.27e-05	0.000228	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CG—melanoma	1e-05	0.00018	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPARG—melanoma	9.65e-06	0.000174	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CD—melanoma	8.79e-06	0.000159	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALB—melanoma	8.68e-06	0.000157	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CB—melanoma	7.66e-06	0.000138	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS2—melanoma	7.59e-06	0.000137	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTEN—melanoma	6.62e-06	0.000119	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CA—melanoma	4.67e-06	8.42e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AKT1—melanoma	3.82e-06	6.88e-05	CbGpPWpGaD
